Department of Otolaryngology-Head and Neck Surgery, Newark, New Jersey, U.S.A.
Laryngoscope. 2014 Apr;124(4):888-95. doi: 10.1002/lary.24371. Epub 2013 Oct 7.
OBJECTIVES/HYPOTHESIS: Extranodal natural killer/T-cell Lymphoma (ENKTL) is a rare, aggressive malignancy that preferentially affects the paranasal region. This study analyzes the demographic, clinicopathologic, incidence, and survival characteristics of sinonasal ENKTL (SN-ENKTL) and extranasal ENKTL (EN-ENKTL) in a comparative fashion.
Retrospective analysis.
The Surveillance, Epidemiology, and End Results database was queried; 528 cases were available for frequency and incidence analysis, and 473 for survival analysis. Data were examined according to age, gender, race, histology, the presence of systemic (or B) symptoms, treatment, and Ann Arbor stage.
Extranasal disease was a poor prognostic factor (hazard ratio [HR] = 1.69, 95% confidence interval [CI] = 1.30-2.19, P < .05). Patients with EN-ENKTL were older (mean 53.8 vs. 49.9 years, P < .05), most were male (72.5% vs. 59.8%, P < .05), and they were more likely to present with stage IIIE/IV disease (38.33% vs. 18.26%, P < .05). B symptoms were present in 38.41% of the EN-ENKTL group (vs. 22.86%, P < .05), and were a poor prognostic factor in this group only (HR = 1.6593, 95% CI = 1.05-2.62, P < .05). Radiation therapy demonstrated a survival advantage among both groups, especially in early stage disease.
SN-ENKTL carries a significantly better prognosis than EN-ENKTL, which presents at more advanced stages. Radiation therapy was associated with increased survival in both groups, especially in cases of localized disease.
2b.
目的/假设:结外自然杀伤/T 细胞淋巴瘤(ENKTL)是一种罕见的侵袭性恶性肿瘤,主要影响鼻窦区域。本研究以对比的方式分析了鼻窦 NK/T 细胞淋巴瘤(SN-ENKTL)和结外 NK/T 细胞淋巴瘤(EN-ENKTL)的人口统计学、临床病理学、发病率和生存特征。
回顾性分析。
查询监测、流行病学和最终结果数据库;有 528 例病例可用于频率和发病率分析,473 例用于生存分析。根据年龄、性别、种族、组织学、是否存在全身(或 B)症状、治疗和安阿伯分期检查数据。
结外疾病是一个不良预后因素(风险比 [HR] = 1.69,95%置信区间 [CI] = 1.30-2.19,P <.05)。EN-ENKTL 患者年龄较大(平均 53.8 岁比 49.9 岁,P <.05),大多数为男性(72.5%比 59.8%,P <.05),且更有可能出现 IIIE/IV 期疾病(38.33%比 18.26%,P <.05)。EN-ENKTL 组 38.41%存在 B 症状(比 22.86%,P <.05),且仅在该组中为不良预后因素(HR = 1.6593,95%CI = 1.05-2.62,P <.05)。放射治疗在两组中均显示出生存优势,特别是在早期疾病中。
SN-ENKTL 的预后明显优于表现为更晚期的 EN-ENKTL。放射治疗与两组的生存增加相关,特别是在局部疾病的情况下。
2b。